Open Access

Characterization of indeterminate renal masses with molecular imaging: how do we turn potential into reality?

  • Steven P. Rowe1Email author,
  • Mehrbod S. Javadi1,
  • Mohamad E. Allaf2 and
  • Michael A. Gorin2
EJNMMI Research20177:34

DOI: 10.1186/s13550-017-0277-0

Received: 14 March 2017

Accepted: 15 March 2017

Published: 12 April 2017

Background

The majority of enhancing renal masses are unable to be effectively characterized as benign or malignant using standard cross-sectional imaging modalities including multi-phase computed tomography (CT) [1] and magnetic resonance imaging (MRI) [2]. This is particularly unfortunate in light of the steady increase in the incidence of these lesions, many of which are discovered incidentally on imaging studies performed for non-urologic indications [3, 4]. Moreover, it has been estimated that upwards of 5600 unnecessary partial and radical nephrectomies are performed each year in the USA for the false presumption of cancer [5]. In light of these data, recently, there has been a growing interest in the use of molecular imaging to characterize the aggressiveness of renal masses [6, 7].

To date, several reports have been published on the ability of 99mTc-sestamibi planar and single photon emission computed tomography (SPECT)/CT imaging to differentiate mitochondrial-rich benign and indolent renal masses such as oncocytomas and hybrid oncocytic/chromophobe tumors (HOCTs) from more aggressive renal tumor histologies including the clear cell subtype of renal cell carcinoma (RCC) [810]. In this issue of European Journal of Nuclear Medicine and Molecular Imaging Research, Tzortzakakis et al. [11] add to this body of literature with a prospective study evaluating 99mTc-sestamibi SPECT/CT in 24 patients with 31 clinically localized T1 renal masses planned for biopsy or surgery. The authors reported that 11 of 12 (92%) oncocytomas and 3 of 3 (100%) HOCTs demonstrated 99mTc-sestamibi uptake, while all other lesions were negative for uptake with the exception of mild uptake in a single papillary RCC. These findings are concordant with earlier studies [9, 10] and dramatically increase the number of 99mTc-sestamibi positive oncocytomas and HOCTs reported in the literature.

As a brief aside, it should be mentioned that there is also a growing interest in the use of renal mass biopsy for determining the histology of renal tumors, particularly as data from two recent systematic reviews have suggested that the rates of complications and non-diagnostic biopsies are tolerable [12, 13]. However, limitations of renal mass biopsy remain, including the intrinsically invasive nature of this procedure, the inaccessibility of some tumors to safe approaches for biopsy, and the heterogeneous population of renal masses that can present as oncocytic neoplasms on biopsy [14, 15]. As such, the non-invasive characterization of renal masses with molecular imaging techniques continues to be of interest and may serve as an adjunct to, or even a replacement of, biopsy in selected cases.

Additional prospective studies

The MIDOR (Molecular Imaging for Differential Diagnosis of Oncocytoma from Renal Cell Carcinoma) Trial, from which the manuscript by Tzortzakakis et al. [11] reports initial results, is the first report in the literature on the implementation of 99mTc-sestamibi SPECT/CT outside of Johns Hopkins Hospital in Baltimore, MD, USA. Additional prospectively collected data are critical for validating the robustness of this imaging test across centers, scanners, and interpreting imaging experts. Ultimately, we can expect that the pearls and pitfalls of using 99mTc-sestambib SPECT/CT for renal mass characterization will become most apparent with increased patient numbers. Additionally, larger datasets are required to ensure that all renal tumor histologies (some of which are quite rare) are studied in sufficient numbers to establish the various patterns of 99mTc-sestamibi uptake.

Development of improved quantitative methods

SPECT imaging has long been considered a qualitative modality; however, new methods for attenuation correction, scatter correction, compensation for distance-dependent blurring/collimator-detector response, and partial volume correction have allowed for true quantitative SPECT to be performed [16]. While both Rowe et al. [9] and Gorin et al. [10] utilized a semi-quantitative method to describe the uptake of 99mTc-sestamibi by renal masses, the method used in these reports (ratio of the highest count voxel in the mass to the highest count voxel in the ipsilateral renal parenchyma) is subject to potential error. Moreover, the images that were used for this analysis were from standard clinical non-quantitative acquisitions.

As Tzortzakakis et al. [11] astutely point out in the “Discussion” section of their manuscript that quantitative methods may be of importance for optimal characterization of renal masses with 99mTc-sestamibi SPECT/CT. Although a visual analysis of renal masses imaged with 99mTc-sestamibi SPECT/CT will always be an important part of interpreting these studies, a numerical threshold (as has been proposed by Gorin et al. [10]) may be a useful interpretational adjunct. However, determination of true SPECT standardized uptake values is likely to be a more reliable means of characterizing these tumors. Thus, further investigation of quantitative SPECT methodologies is needed.

Pipeline of new radiotracers

The promise of 99mTc-sestamibi SPECT/CT must be tempered by the fact that an imaging test that uses a single radiotracer can provide only limited information for characterizing indeterminate renal masses. Indeed, while 99mTc-sestamibi uptake appears to allow for the reliable identification of benign/indolent oncocytomas and HOCTs [911], not all masses that fail to accumulate 99mTc-sestamibi will behave in an aggressive manner (e.g., chromophobe RCC and low-grade papillary RCCs). As such, the use of other radiotracers in addition to 99mTc-sestamibi may allow for more complete risk stratification. Already, the radiolabeled monoclonal antibody 124I-girentuximab has been used in a phase III clinical trial to identify clear cell RCCs using positron emission tomography (PET) imaging through binding to carbonic anhydrase IX (CAIX), a cell surface enzyme that is not expressed in normal renal tissue or by other renal tumor histologies [17]. New small molecule SPECT and PET radiotracers that target carbonic anhydrase IX are in preclinical development (for example [18] and [19]). The SPECT agent described in Yang et al. [18] is of particular interest given its labeling with 111In which would allow for dual radiotracer SPECT in combination with 99mTc-sestamibi.

Although lacking dual radiotracer capability, PET does have advantages over SPECT including established methods of quantitation and superior spatial resolution. As such, the development of PET radiotracers for renal mass characterization should be of significant interest to the field. As noted above, a CAIX PET radiotracer (124I-girentuximab) has already been extensively studied and may prove clinically useful in the future [17]. Furthermore, mitochondrial PET imaging agents have been described for cardiac and non-cardiac applications [20, 21] and deserve to be explored for their potential utility in identifying mitochondrial-rich renal masses such as oncocytomas and HOCTs.

Conclusions

The work of Tzortzakakis and coworkers [11] is a critical step in laying the foundation for the widespread use of molecular imaging for renal mass characterization, although further efforts would be of value for advancing the field to the point of routine clinical application. Additional prospectively collected data as well as research in quantitative imaging methods and the development novel radiotracers could usher in an era of non-invasive renal mass characterization. The refinement of molecular imaging techniques for renal mass characterization should be a priority for nuclear medicine, as this has the potential to greatly benefit patients by sparing many of the morbidity of invasive procedures in addition to unnecessary renal surgery.

Notes

Abbreviations

CAIX: 

Carbonic anhydrase IX

CT: 

Computed tomography

HOCT: 

Hybrid oncocytic/chromophobe tumor

MIDOR: 

Molecular Imaging for Differential Diagnosis of Oncocytoma from Renal Cell Carcinoma

MRI: 

Magnetic resonance imaging

PET: 

Positron emission tomography

RCC: 

Renal cell carcinoma

SPECT: 

Single photon emission computed tomography

Declarations

Authors’ contributions

All authors contributed to the conceptualizing and drafting of the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors’ Affiliations

(1)
Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine
(2)
The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine

References

  1. Pierorazio PM, Hyams ES, Tsai S, et al. Multiphasic enhancement patterns of small renal masses (≤4 cm) on preoperative computed tomography: utility for distinguishing subtypes of renal cell carcinoma, angiomyolipoma, and oncocytoma. Urology. 2013;81:1265–71.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Pedrosa I, Sun MR, Spencer M, et al. MR imaging of renal masses: correlation with findings at surgery and pathologic analysis. Radiographics. 2008;28:985–1003.View ArticlePubMedGoogle Scholar
  3. Gill IS, Aron M, Gervais DA, Jewett MA. Clinical practice. Small renal mass. N Engl J Med. 2010;362:624–34.View ArticlePubMedGoogle Scholar
  4. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006;98:1331–4.View ArticlePubMedGoogle Scholar
  5. Johnson DC, Vukina J, Smith AB, et al. Preoperatively misclassified, surgically removed benign renal masses: a systematic review of surgical series and United States population level burden estimate. J Urol. 2015;193:30–5.View ArticlePubMedGoogle Scholar
  6. Gorin MA, Rowe SP, Allaf ME. Nuclear imaging of renal tumours: a step towards improved risk stratification. Nat Rev Urol. 2015;12:445–50.View ArticlePubMedGoogle Scholar
  7. Gorin MA, Rowe SP, Allaf ME. Noninvasive determination of renal tumor histology utilizing molecular imaging. Urol Oncol. 2016;34:525–8.View ArticlePubMedGoogle Scholar
  8. Gormley TS, Van Every MJ, Moreno AJ. Renal oncocytoma: preoperative diagnosis using technetium 99 m sestamibi imaging. Urology. 1996;48:33–9.View ArticlePubMedGoogle Scholar
  9. Rowe SP, Gorin MA, Gordetsky J, et al. Initial experience using 99mTc-MIBI SPECT/CT for the differentiation of oncocytoma from renal cell carcinoma. Clin Nucl Med. 2015;40:309–13.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Gorin MA, Rowe SP, Baras AS, et al. Prospective evaluation of (99m)Tc-sestamibi SPECT/CT for the diagnosis of renal oncocytomas and hybrid oncocytic/chromophobe tumors. Eur Urol. 2016;69:413–6.View ArticlePubMedGoogle Scholar
  11. Tzortzakakis A, Gustafsson O, Karlsson M, Ekström-Ehn L, Ghaffarpour R, Axelsson R. Visual evaluation and differentiation of renal oncocytomas from renal cell carcinomas by means of 99mTc-sestamibi SPECT/CT. EJNMMI Res. 2017;7:29.View ArticlePubMedGoogle Scholar
  12. Marconi L, Dabestani S, Lam TB, et al. Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy. Eur Urol. 2016;69:660–73.View ArticlePubMedGoogle Scholar
  13. Patel HD, Johnson MH, Pierorazio PM, et al. Diagnostic accuracy and risks of biopsy in the diagnosis of a renal mass suspicious for localized renal cell carcinoma: systematic review of the literature. J Urol. 2016;195:1340–7.View ArticlePubMedGoogle Scholar
  14. Gorin MA, Rowe SP, Allaf ME. Oncocytic neoplasm on renal mass biopsy: a diagnostic conundrum. Oncology (Williston Park). 2016;30:426–35.Google Scholar
  15. Patel HD, Druskin SC, Rowe SP, Pierorazio PM, Gorin MA, Allaf ME. Surgical histopathology for suspected oncocytoma on renal mass biopsy: a systematic review and meta-analysis. BJU Int. 2017, in press.Google Scholar
  16. Bailey DL, Willowson KP. An evidence-based review of quantitative SPECT imaging and potential clinical applications. J Nucl Med. 2013;54:83–9.View ArticlePubMedGoogle Scholar
  17. Divgi CR, Uzzo RG, Gatsonis C, et al. Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol. 2013;31:187–94.View ArticlePubMedGoogle Scholar
  18. Yang X, Minn I, Rowe SP, et al. Imaging of carbonic anhydrase IX with an 111In-labeled dual-motif inhibitor. Oncotarget. 2015;6:33733–42.PubMedPubMed CentralGoogle Scholar
  19. Minn I, Koo SM, Lee HS, et al. [64Cu]XYIMSR-06: a dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma. Oncotarget. 2016;7:56471–9.PubMedPubMed CentralGoogle Scholar
  20. Madar I, Isoda T, Finley P, Angle J, Wahl R. 18F-fluorobenzyl triphenyl phosphonium: a noninvasive sensor of brown adipose tissue thermogenesis. J Nucl Med. 2011;52:808–14.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Berman DS, Maddahi J, Tamarappoo BK, et al. Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography. J Am Coll Cardiol. 2013;61:469–77.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017